GlassScriptPhysician profile
Prarthana Jain
NPI 1497314538
$5,558.17
in general payments reported to CMS, 2019-2025
23 companies · $5,342 in 2025
The $5,342 reported for 2025 was more than what 86% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $111 · 2024: $105 · 2025: $5,342.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,637 · Consulting Fee: $1,800 · Education: $121.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,637.05 |
| Consulting Fee | $1,800.00 |
| Education | $121.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $2,366.06 | 2025 | Tremfya, Simponi Aria |
| Amgen INC. | $524.07 | 2024-2025 | Otezla, Krystexxa, Tavneos |
| Abbvie INC. | $407.40 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $271.19 | 2025 | |
| Lilly USA, LLC | $228.18 | 2025 | Taltz, Zepbound |
| Ucb, INC. | $221.54 | 2024-2025 | Bimzelx |
| Organon LLC | $181.57 | 2025 | Hadlima |
| Astrazeneca Pharmaceuticals LP | $177.65 | 2023-2025 | Saphnelo |
| Fresenius Kabi USA, LLC | $155.24 | 2025 | |
| Pfizer INC. | $134.88 | 2025 | |
| Glaxosmithkline, LLC. | $134.21 | 2025 | Benlysta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $128.79 | 2025 | Ofev |
| Genzyme Corporation | $114.47 | 2024-2025 | |
| Almatica Pharma LLC | $85.82 | 2025 | Teriparatide |
| Janssen Scientific Affairs, LLC | $80.81 | 2025 | Tremfya |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $66.66 | 2025 | Purified Cortrophin Gel |
| Genentech USA, INC. | $65.94 | 2025 | Actemra, Gazyva |
| Sandoz INC. | $63.88 | 2025 | Jubbonti, Hyrimoz |
| E.R. Squibb & Sons, L.L.C. | $56.30 | 2025 | Orencia |
| Alexion Pharmaceuticals, INC. | $47.26 | 2025 | Strensiq |
| Tersera Therapeutics LLC | $18.96 | 2025 | Quzyttir |
| Depuy Synthes Sales INC. | $14.12 | 2025 | Orthovisc, Monovisc |
| Janssen Pharmaceuticals, INC | $13.17 | 2025 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Prarthana Jain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.